Treatment of B-cell Prolymphocytic Leukemia with Normal TP53
B-cell prolymphocytic leukemia (B-PLL) is a rare mature B-cell malignancy. TP53 status is a critical factor in determining the appropriate first-line approach, as it divides patients into two distinct management groups.
Clinical scenario: B-cell prolymphocytic leukemia confirmed to have normal TP53 — no TP53 deletion and no TP53 mutation. This applies to approximately half of B-PLL cases and carries distinct treatment implications compared to TP53-altered disease.
First-line approach
In patients with B-PLL and confirmed normal TP53 status, the standard first-line strategy involves combination chemo-immunotherapy. The full regimen options, agent selection, and sequencing details are outlined in the structured protocol.
References
- However, for the 50% of cases with normal TP53, a conventional chemo-immunotherapy approach with FCR or bendamustine and rituximab is reasonable.
- For T-PLL, first-line therapy is with intravenous alemtuzumab and for B-PLL is with combination chemo-immunotherapy for patients with normal TP53 and with alemtuzumab or BCR inhibitors for those with deletions or mutations of TP53.
DOI: 10.1182/asheducation-2015.1.361
View source ↗